logo-loader
viewEmerald Health Therapeutics Inc

Emerald Health Therapeutics' joint venture receives TSX Venture Exchange conditional approval

The Vancouver-based company will invest C$5 million for a 51% equity stake in Emerald Health Naturals

handshake
Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals

Emerald Health Therapeutics Inc (CVE:EMH, OTCMKTS:EMHTF) said Monday that it has received conditional approval from the TSX Venture Exchange for its joint venture with San Diego-based Emerald Health Bioceuticals (EHB).

Vancouver-based Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals.

READ: Emerald Health Therapeutics files 17 US patent applications to protect product line

EHB will grant the joint venture exclusive Canadian distribution rights to its product line in exchange for 49% equity ownership. EHB’s products consist of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system of neurotransmitters that bind to cannabinoid receptors.

Market research commissioned by Emerald Health Therapeutics has found that about 60% of legal cannabis users also use natural health products.

Shares of Emerald Health Therapeutics slipped C$0.18 to C$3.74 in Canada. They slipped US$0.16 to US$2.84 in OTC trading.


Contact Dennis Fitzgerald at [email protected]
 

Quick facts: Emerald Health Therapeutics Inc

Price: 1 CAD

TSX-V:EMH
Market: TSX-V
Market Cap: $149.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: PharmaCielo looking to 2020 as a transformative year for the...

PharmaCielo (CVE: PCLO) Chief Corporate Officer David Gordon joined Steve Darling from Proactive in Toronto to talk about the cannabis company whose operations are in Colombia. Gordon talked about the facilities they have and the advantages the climate in Colombia has for...

11 hours, 4 minutes ago

2 min read